Overview
Financials
Units: $M (per-share in $, ratios in %)Revenue & profit
Margins
Valuation
Multiples at each fiscal year end (annual) and current (TTM)Valuation history
Segments
Revenue breakdown (annual, $B). Segments depend on each year’s disclosure.By product
By region
Dividends & earnings
Annual dividend per share ($, split-adjusted)
EPS (diluted), last 16 quarters ($)
Company info
Biofrontera Inc. is a biopharmaceutical firm specializing in the commercialization of pharmaceutical solutions for skin-related ailments across the United States. Its product lineup features Ameluz, a prescription drug employed with the BF-RhodoLED lamp series for photodynamic therapy. This treatment is designed for both localized and broader area management of mild-to-moderate actinic keratosis on the face and scalp. Additionally, the company offers Xepi, a topical, non-fluorinated quinolone that functions by inhibiting bacterial growth to treat impetigo. Established in 2015, Biofrontera Inc. is headquartered in Woburn, Massachusetts.